Compare · ABT vs TLX
ABT vs TLX
Side-by-side comparison of Abbott Laboratories (ABT) and Telix Pharmaceuticals Limited (TLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and TLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 50.7x TLX ($3.96B).
- Over the past year, ABT is down 11.8% and TLX is down 6.8% - TLX leads by 4.9 points.
- ABT has been more active in the news (8 items in the past 4 weeks vs 3 for TLX).
- ABT has more recent analyst coverage (25 ratings vs 6 for TLX).
- Company
- Abbott Laboratories
- Telix Pharmaceuticals Limited
- Price
- -
- -
- Market cap
- $200.95B
- $3.96B
- 1M return
- +11.04%
- +17.20%
- 1Y return
- -11.76%
- -6.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest TLX
- SEC Form 6-K filed by Telix Pharmaceuticals Limited
- Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
- Telix to Host R&D Day in New York City on September 22, 2026
- Telix H1 2026 Results: Investor Webcast Notification
- TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
- SEC Form 6-K filed by Telix Pharmaceuticals Limited
- Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
- Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
- Telix Pharmaceuticals downgraded by RBC Capital Mkts
- SEC Form 6-K filed by Telix Pharmaceuticals Limited